10x Genomics–Fidelity: investment, 201804 financing round Series D totalling $50m incl existing co-investor Fidelity |
2018-04-26 |
10x Genomics–Fidelity: investment, 201901 financing round Series D extension totalling $35m incl existing + co-investor Fidelity |
2019-01-07 |
10x Genomics–Merck (DE): CRISPR technology, 202006 collab launch integrated solution for CRISPR research |
2020-06-10 |
10x Genomics–Meritech Capital: investment, 201804 financing round Series D totalling $50m incl new + lead investor Meritech Capital Partners |
2018-04-26 |
10x Genomics–Meritech Capital: investment, 201901 financing round Series D extension totalling $35m incl existing + lead investor Meritech Capital |
2019-01-07 |
10x Genomics–Paladin Capital: investment, 201804 financing round Series D totalling $50m incl existing co-investor Paladin Capital |
2018-04-26 |
10x Genomics–PerkinElmer: DNA sequencing technology, 201701– collab joint offering of automated NGS solutions |
2017-01-09 |
10x Genomics–SEVERAL: investment, 201804 financing round Series D $50m led by Meritech Capital Partners |
2018-04-26 |
10x Genomics–SEVERAL: investment, 201901 financing round Series D extension $35m led by Meritech Capital + incl Fidelity + Wells Fargo |
2019-01-07 |
10x Genomics–SEVERAL: investment, 201908–201909 IPO $390m+$58.5m with 10m+1.5m shares common stock at $39/share Nasdaq Global Select Market |
2019-08-19 |
10x Genomics–SEVERAL: investment, 202009 public offering $440m+$66m with 4m+600k shares Class A common stock at $110/share |
2020-09-08 |
10x Genomics–SoftBank: investment, 201804 financing round Series D totalling $50m incl existing co-investor SoftBank Group |
2018-04-26 |
10x Genomics–SVB: credit, 201804– debt facility $75m with Silicon Valley Bank |
2018-04-26 |
10x Genomics–Wells Fargo: investment, 201804 financing round Series D totalling $50m incl new + co-investor Wells Fargo Strategic Capital |
2018-04-26 |
10x Genomics–Wells Fargo: investment, 201901 financing round Series D extension totalling $35m incl existing + co-investor Wells Fargo |
2019-01-07 |
1910 Genetics–SEVERAL: investment, 2018c seed financing round $4.1m led by Sam Altman |
2018-01-01 |
1910 Genetics–SEVERAL: investment, 202103 financing round Series A $22m co-led by M12 + Playground Global |
2021-03-23 |
3a-Diagnostics–XPhyto Therapeutics: investment, 202107– 202110 acqisition 100% €400k upfront + €3.5m at closing ANNOUNCED |
2021-07-20 |
3EO Health–Harvard Univ: nucleic acid diagnostics, 202208– license ww excl from Wyss Institute for portable nucleic acid detection technology |
2022-08-04 |
3SBio–Verseau Therapeutics: cancer immunotherapy, 201902– collab MAbs developm + excl commercialisation in Greater China €na incl $15m investment |
2019-02-11 |
4BIO Ventures–SEVERAL: investment, 201909 first closing $50m of 4BIO Ventures II fund targeting $150m |
2019-09-09 |
4D Lifetec–SEVERAL: investment, 202207 financing round Series B CHF1.9m first closing from existing + new investors + strategic partners |
2022-07-11 |
4Pharma–BC Platforms: investment, 202306 acquisition €na of 4Pharma by BC Platforms |
2023-06-01 |
4SC–SEVERAL: investment, 201706–201707 cash capital increase €41m with 11.68m new shares at €3.5/share |
2017-06-12 |
4titude–Brooks Automation: investment, 201710 acquisition $65m in cash of 4titude Ltd by Brooks |
2017-10-05 |
54gene–SEVERAL: investment, 201907 seed financing round $4.5m |
2019-07-01 |
54gene–SEVERAL: investment, 202004 financing round Series A $15m led by Adjuvant Capital |
2020-04-14 |
54gene–SEVERAL: investment, 202109 financing round Series B $25m led by Cathay AfricInvest Innovation Fund |
2021-09-16 |
64x Bio–Fifty Years: investment, 202011 seed financing round totalling $4.5m disclosed incl co-lead investor Fifty Years |
2020-11-16 |
64x Bio–First Round Capital: investment, 202011 seed financing round totalling $4.5m disclosed incl co-lead investor First Round Capital |
2020-11-16 |
64x Bio–KKH Advisors: public relations, 202201 service existent by KKH Advisors |
2022-01-19 |
64x Bio–LifeForce Capital: investment, 202201 financing round Series A totalling $55m incl new + lead investor LifeForce Capital |
2022-01-19 |
64x Bio–Refactor Capital: investment, 202011 seed financing round totalling $4.5m disclosed incl co-lead investor Refactor Capital |
2020-11-16 |
64x Bio–SEVERAL: investment, 202011 seed financing round $4.5m disclosed as 64x Bio emerges from stealth |
2020-11-16 |
64x Bio–SEVERAL: investment, 202201 financing round Series A $55m led by Lifeforce Capital |
2022-01-19 |
908 Devices–ARCH Venture: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor ARCH Ventures |
2019-04-29 |
908 Devices–Casdin Capital: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Casdin Capital |
2019-04-29 |
908 Devices–Manufacturing USA: grant, 201907– grant from NIIMBL for developm of at-line bioreactor process analytics tog w MilliporeSigma et al |
2019-07-25 |
908 Devices–Northpond Ventures: investment, 201904 financing round Series E totalling $17.5m incl new + lead investor Northpond Ventures |
2019-04-29 |
908 Devices–Razor’s Edge Ventures: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Razor’s Edge Ventures |
2019-04-29 |
908 Devices–Sands Capital: investment, 201904 financing round Series E totalling $17.5m incl new + co-investor Sands Capital Ventures |
2019-04-29 |
908 Devices–Sartorius: bioprocess control technology, 202106 collab product integration Rebel media analyzer with SIMCA data exploratory tool |
2021-06-22 |
908 Devices–Saudi Arabia: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Saudi Aramco Energy Ventures |
2019-04-29 |
908 Devices–Schlumberger: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Schlumberger |
2019-04-29 |
908 Devices–Securecell: bioprocess control technology, 202106 collab product integration Rebel media analyzer with Lucullus PIMS |
2021-06-22 |
908 Devices–SEVERAL: investment, 201703 financing round Series D $20m from new investors Tao Capital + Cormorant + existing investors |
2017-03-15 |
908 Devices–SEVERAL: investment, 201904 financing round Series E $17.5m led by new investor Northpond Ventures |
2019-04-29 |
908 Devices–SEVERAL: investment, 202012 IPO $130m+$19.5m net $136.6m with 6.5m+975k shares common stock at $20/share at Nasdaq Global Market |
2020-12-18 |
908 Devices–SEVERAL: investment, 202111 public offering $100.8m net $94.4m with 3.15m shares common stock at $32/share |
2021-11-15 |
908 Devices–Tao Capital: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Tao Capital Partners |
2019-04-29 |
A-Alpha Bio–Lux Capital: investment, 202109 financing round Series A totalling $20m incl co-investor Lux Capital |
2021-09-08 |
A-Alpha Bio–Madrona Venture: investment, 202109 financing round Series A totalling $20m incl lead investor Madrona Venture Group |
2021-09-08 |
A-Alpha Bio–Perceptive Advisors: investment, 202109 financing round Series A totalling $20m incl co-investor Perceptive Xontogeny Venture Fund |
2021-09-08 |
A-Alpha Bio–SEVERAL: investment, 202109 financing round Series A $20m led by Madrona Venture Group |
2021-09-08 |
Aadi Bioscience–Celgene: mTOR inhibitor, 2014– license for ABI-009 to Aadi Bioscience |
2014-01-01 |
Aadi Bioscience–Helsinn: investment, 201705 financing round Series A totalling $23m incl $2m from co-investor Helsinn Investment Fund |
2017-05-08 |
Aadi Bioscience–SEVERAL: investment, 201705 financing round Series A $23m led by Hermed Capital with Celgene + Vivo Capital + Helsinn et al |
2017-05-08 |
AAIPharma Services–Cambridge Major Laboratories: investment, 201312 merger in late 2013 |
2013-12-31 |
Aalto Bio Reagents–Biosynth Carbosynth: investment, 202205 acquisition of Aalto by Biosynth Carbosynth |
2022-05-25 |
AAVantgarde Bio–SEVERAL: investment, 202306 financing round Series A €61m led by Atlas Venture + Forbion |
2023-06-06 |
AavantiBio–Bain Capital: investment, 202010 financing round Series A totalling $107m incl investor Bain Capital Life Sciences |
2020-10-22 |
AavantiBio–Perceptive Advisors: investment, 202010 financing round Series A totalling $107m incl investor Perceptive Advisors |
2020-10-22 |
AavantiBio–RA Capital: investment, 202010 financing round Series A totalling $107m incl investor RA Capital Management |
2020-10-22 |
AavantiBio–Sarepta: investment, 202010 financing round Series A totalling $107m incl $15m from Sarepta Therapeutics |
2020-10-22 |
AavantiBio–SEVERAL: investment, 202010 financing round Series A $107m from Perceptive Advisors + Bain Capital LS + RA Capital + Sarepta |
2020-10-22 |
AB Science–RA Capital: investment, 201604 private placement €12m with 764,820 shares at €15.69/share with attached 191,205 warrants |
2016-04-18 |
AB Science–SEVERAL: investment, 201604 private placement €12m w 765k new shares at €15.69/share |
2016-04-18 |
AB Science–SEVERAL: investment, 201703 private placement €19m net €18.43m w 1.24m new shares at €15.3/share |
2017-03-31 |
Abata Therapeutics–SEVERAL: investment, 202106 financing round Series A $95m led by seed investor Third Rock Ventures |
2021-06-23 |
Abaxis–Zoetis: investment, 201805–201807 acquisition $2b for $83/share in cash |
2018-05-16 |
AbbVie–908 Devices: sample separation technology, 201806 supply existent use of ZipChip by AbbVie |
2018-06-04 |
AbbVie–Apogenix: TRAIL receptor agonists, 201407 aquisition of ww rights to all TRAIL receptor agonists of Apogenix by AbbVie |
2014-07-01 |
AbbVie–Argenx: SIMPLE antibodies, 201604– collob $40m upfront + $645m milestones + royalties developm + commerc of ARGX-115 |
2016-04-01 |
AbbVie–Capsida Biotherapeutics: gene therapy, 202104– collab $80m upfront + $530m milestones + royalties capsids for 3 CNS gene therapy targets |
2021-04-29 |
AbbVie–Frontier Medicines: E3 ligase degraders, 202012– strategic global collab $55m upfront + cost reimbursement + >1$b milestones + royalties |
2020-12-02 |
AbbVie–Harpoon Therapeutics: cancer immunotherapy, 201710– collab research €na using TriTAC platform to discover drugs against AbbVie I-O targets |
2017-10-18 |
AbbVie–Inventiva: pharmaceutical, 201702 collab RnD existent |
2017-02-15 |
AbbVie–Mission Therapeutics: DUB inhibitors, 201811– collab RnD + license option €na for Alzheimer’s + Parkinson’s diseases |
2018-11-15 |
AbbVie–Temedica: digital patient companion app, 202308 collab launch of companion app Tami for patients with chronic IBD in Germany |
2023-08-02 |
AbbVie–Teneobio: antibody cancer drug, 201902– collab $90m upfront + milestones RnD + right to acquire TNB-383B via TeneoOne Inc |
2019-02-11 |
AbbVie–Voyager Therapeutics: AAV technology, 201802– collab ww excl $69m upfront +>$1b milestones + royalties developm vectorised tau-Abs for AD |
2018-02-20 |
AbbVie–Voyager Therapeutics: AAV technology, 201902– collab ww excl $65m upfront +>$1b milestones + royalties developm vectorised Abs for PD |
2019-02-22 |
Abcam–BrickBio: antibody technology, 201911– collab use of BrickBio conjugation technology for research + diagnostic antibodies |
2019-11-08 |
Abcam–Danaher: investment, 202308– acquisition $24/share in cash = enterprise value $5.7b incl assumed indebtedness + net of acquired cash |
2023-08-28 |
Abcam–SEVERAL: investment, 202010 US IPO $156.5m+23.5m with 8.95m+1.34m ADSs at $17.5/ADS at Nasdaq Global Market |
2020-10-19 |
AbCellera–DCVC: investment, 201809 financing round Series A totalling $10m incl lead investor DCVC Bio |
2018-09-27 |
AbCellera–Harbour BioMed: drug discovery services, 201805– collab integration single-cell Ab discovery services w H2L2 transgenic mouse platform |
2018-05-30 |
AbCellera–SEVERAL: investment, 201809 financing round Series A $10m led by DCVC Bio |
2018-09-27 |
AbeXXa Biologics–Boehringer: investment, 201712 existent investment by BIVF |
2017-12-11 |
ABF–Genedata: bioinformatics, 201707– supply expansion use of Genedata Selector by AB Enzymes for decision support |
2017-07-11 |
Abide Therapeutics–Lundbeck: investment, 201905 acquisition $250m upfront + $150m milestones of Abide by Lundbeck |
2019-05-06 |
Abingworth–Carlyle: investment, 202204–202208 acquisition €na of Abingworth by Carlyle |
2022-04-11 |
Abingworth–Goodwin Procter: legal services, 201807 supply service legal counsel for $315m Abingworth Bioventures VII Fund |
2018-07-09 |
Abingworth–Huntsworth: public relations, 202102 service existent by Citigate Dewe Rogerson |
2021-02-03 |
Abingworth–SEVERAL: investment, 201807 final closing of $315m Abingworth Bioventures VII Fund |
2018-07-09 |
Abingworth–SEVERAL: investment, 202102 final closing at $465m of Abingworth Bioventures 8 Fund |
2021-02-03 |
Abingworth–SEVERAL: investment, 202105 final closing at $582m of Abingworth Clinical Co-Development Fund 2 |
2021-05-10 |
Abivax–Column Group: investment, 202209 reserved equity capital increase totalling €46.2m incl new + lead investor TCG X |
2022-09-02 |
Abivax–Deep Track Capital: investment, 202209 reserved equity capital increase totalling €46.2m incl new + co-investor Deep Track Capital |
2022-09-02 |
Abivax–Invus Group: investment, 202209 reserved equity capital increase totalling €46.2m incl co-investor Invus |
2022-09-02 |